https://scholars.lib.ntu.edu.tw/handle/123456789/554368| Title: | An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases | Authors: | Husseini, Jad S Amorim, Bárbara Juarez Torrado-Carvajal, Angel Prabhu, Vinay Groshar, David Umutlu, Lale Herrmann, Ken Cañamaque, Lina García Garzón, José Ramón García Palmer, William E Heidari, Pedram TIFFANY TING-FANG SHIH Sosna, Jacob Matushita, Cristina Cerci, Juliano Queiroz, Marcelo Muglia, Valdair Francisco Nogueira-Barbosa, Marcello H Borra, Ronald J H Kwee, Thomas C Glaudemans, Andor W J M Evangelista, Laura Salvatore, Marco Cuocolo, Alberto Soricelli, Andrea Herold, Christian Laghi, Andrea Mayerhoefer, Marius Mahmood, Umar Catana, Ciprian Daldrup-Link, Heike E Rosen, Bruce Catalano, Onofrio A |
Keywords: | MR; Metastases; Osseous; PET; PET/MR; PET/MRI; Skeletal | Issue Date: | 22-Feb-2021 | Source: | European journal of nuclear medicine and molecular imaging | Abstract: | MR is an important imaging modality for evaluating musculoskeletal malignancies owing to its high soft tissue contrast and its ability to acquire multiparametric information. PET provides quantitative molecular and physiologic information and is a critical tool in the diagnosis and staging of several malignancies. PET/MR, which can take advantage of its constituent modalities, is uniquely suited for evaluating skeletal metastases. We reviewed the current evidence of PET/MR in assessing for skeletal metastases and provided recommendations for its use. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/554368 | ISSN: | 16197070 | DOI: | 10.1007/s00259-021-05198-2 | SDG/Keyword: | [SDGs]SDG3 dotanoc ga 68; edotreotide ga 68; fluciclovine f 18; fluorodeoxyglucose f 18; gallium dotatate ga 68; prostate specific membrane antigen f 18; prostate specific membrane antigen ga 68; sodium fluoride f 18; tracer; unclassified drug; radiopharmaceutical agent; adult; Article; bone metastasis; breast cancer; cancer diagnosis; cancer staging; consensus; diagnostic value; human; lung cancer; lymphoma; neuroendocrine tumor; nuclear magnetic resonance imaging; positron emission tomography; positron emission tomography-computed tomography; primary tumor; prostate adenocarcinoma; radiation dose; well differentiated neuroendocrine tumor; expert witness; nuclear magnetic resonance imaging; positron emission tomography; positron emission tomography-computed tomography; Expert Testimony; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radiopharmaceuticals |
| Appears in Collections: | 醫學院附設醫院 (臺大醫院) |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.